RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase 1/Phase 2

Registered title, quoted from ClinicalTrials.gov

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 4 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 4

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study sitePeking University Cancer Hospital北京大学肿瘤医院BeijingHospital page
  2. Study siteSecond Affiliated Hospital of Soochow University苏州大学附属第二医院SuzhouHospital page
  3. Study siteShandong Cancer Hospital and Institute山东省肿瘤医院JinanHospital page
  4. Study siteZhongshan Hospital, Fudan University复旦大学附属中山医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT05786924, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Histologically or cytologically confirmed recurrent locally advanced (unresectable) or metastatic solid tumors with documented RAS or RAF mutations or alterations.

    Inclusion criterion 2

  3. Cancer that has a known MEK1/2 mutation.

    Exclusion criterion 1

    Evidence of active malignancy (other than study-specific malignancies) requiring systemic therapy within the next 2 years.

    Exclusion criterion 10

  4. Females who are pregnant or breastfeeding.

    Exclusion criterion 12

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05786924, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Key Inclusion Criteria:

  • Life expectancy of ≥ 12 weeks in the opinion of the investigator.
  • Histologically or cytologically confirmed recurrent locally advanced (unresectable) or metastatic solid tumors with documented RAS or RAF mutations or alterations.
  • Adequate bone marrow and organ function.
  • Recovered from toxicity to prior anti-cancer therapy.

Part 1 Dose Escalation cohort ONLY:

  • Part 1A: Advanced/metastatic NSCLC with KRAS non-G12C, HRAS, NRAS, BRAF or CRAF (RAF1) mutations or alterations
  • Part 1B: Advanced/metastatic GI tumors (e.g., PDAC, CRC, and BTC) with KRAS, HRAS, NRAS, BRAF, or CRAF (RAF1) mutations or alterations
  • Part 1D: Colorectal adenocarcinoma with KRAS, HRAS, NRAS, BRAF, or CRAF (RAF1) mutations or alterations
  • Part 1E: Other advanced/metastatic non-GI, non-NSCLC solid tumors with KRAS, HRAS, NRAS, BRAF, or CRAF (RAF1) mutations or alterations
  • Part 1F: Solid tumors with BRAF or NRAS mutations or alterations
  • Part 1G: Solid tumors with BRAF or NRAS mutations or alterations

Part 2 Dose Optimization and Expansion cohorts ONLY:

  • Part 2A: Advanced/metastatic NSCLC with BRAF mutations or alterations
  • Part 2A2: Advanced/metastatic NSCLC with BRAF mutations or alterations
  • Part 2B2: Advanced/metastatic CRC with KRAS, HRAS, NRAS, BRAF, or CRAF (RAF1) mutations or alterations
  • Part 2B3: Advanced/metastatic BTC (adenocarcinoma) with KRAS, HRAS, NRAS, BRAF, or CRAF (RAF1) mutations or alterations
  • Part 2B4: Advanced/metastatic non-CRC GI cancer (adenocarcinoma) with KRAS mutations or alterations
  • Part 2D1: Advanced/metastatic CRC (adenocarcinoma) with BRAF mutations or alterations
  • Part 2F: Advanced/metastatic tumor type with KRAS non-G12C, and/or BRAF mutations or alterations

Key Exclusion Criteria:

  • Cancer that has a known MEK1/2 mutation.
  • Known allergy/hypersensitivity to excipients of S241656 or to any of the registered IMPs administered in combination.
  • Any contraindication, to the use of any of the combination agents administered as part of the assigned cohort, including failure to meet the regimen-specific ANC requirements
  • Major surgery within 4 weeks of study entry or planned during study.
  • Ongoing anticancer therapy.
  • Ongoing radiation therapy.
  • Uncontrolled or active clinically relevant bacterial, fungal, or specific viral infection requiring systemic therapy.
  • Clinically significant cardiovascular disease.
  • Symptomatic spinal cord compression.
  • Evidence of active malignancy (other than study-specific malignancies) requiring systemic therapy within the next 2 years.
  • History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO.
  • Females who are pregnant or breastfeeding.
  • Actively receiving systemic treatment or direct medical intervention on another therapeutic clinical study.
  • Prior use of experimental agents that target the KRAS/BRAF/MEK/ERK pathway.
  • Part 1F: Any ocular abnormality, active myositis or myopathy or history of rhabdomyolysis, or severe dermatologic condition
  • Part 1G: Active autoimmune disease, severe dermatologic condition, or systemic treatment with corticosteroids

Quoted from ClinicalTrials.gov, NCT05786924, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT05786924, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT05786924